Metral
Markets

Heart drug developer Kardigan is targeting a $1.4 billion valuation in its U.S. IPO

The Princeton, N.J., biotech plans to raise up to $373.3 million by selling 23.3 million shares priced between $14 and $16 each

M
Metral Newsroom
Editorial Desk
· 2 min read
𝕏 in ✉
Heart drug developer Kardigan is targeting a $1.4 billion valuation in its U.S. IPO

Heart drug developer Kardigan is targeting a $1.4 billion valuation in its U.S. IPO

Published June 11, 2026 · Category: Markets

Overview

The Princeton, N.J., biotech plans to raise up to $373.3 million by selling 23.3 million shares priced between $14 and $16 each

Source

Originally published at qz.com.

Related Articles

CD
Metral Newsroom

Metral covers global markets, stocks, crypto and the economy — desk research and data-driven analysis. Tip our newsroom: [email protected]

Email the newsroom →
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.

Related Stories

More from Financial News →
Micron ties its future to Anthropic in supply deal
Markets

Micron ties its future to Anthropic in supply deal
Oil prices fall after US waives Iran sanctions and peace talks in Switzerland progress – business live
Markets

Oil prices fall after US waives Iran sanctions and peace talks in Switzerland progress – business live
Australia's coal and gas exports violate our human rights, group says in new UN case
Markets

Australia's coal and gas exports violate our human rights, group says in new UN case
Amazon is selling a 2-in-1 laptop and tablet for just $73 during Prime Day
Markets

Amazon is selling a 2-in-1 laptop and tablet for just $73 during Prime Day